Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at [email protected].
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
S&P Global
When The Cycle Turns: Contract Research Organizations Are Well Positioned To Weather A Storm
Annual pharma and biotech R&D spending remained largely flat from 2008 to 2010 at about $130 billion, per EvaluatePharma.
El Global
Ten drugs that will revolutionize the market in 2020
Although the FDA approves an average of half a hundred new drugs every year, few are really called to obtain large sales in the market. In fact, the consultant Evaluate…
Handelsblatt
For Big Pharma, the signs continue to point to growth
The British company EvaluatePharma, which broadly aggregates analysts' estimates, expects the pharmaceutical industry to generate around $ 50 billion in additional sales…
Neue Zürcher Zeitung
There has been considerable progress in breast cancer, but lung cancer is far from being defeated
Keytruda is well on the way to becoming the most profitable drug in the world within a few years.
El Pais
Pharmaceuticals beat a record of mergers on the hunt for new drugs
By 2022 the global market will break the billion dollar barrier. In 2024 it will reach $1.18 billion (1.04 billion euros), according to a report by the consultant…
The Pharma Letter
Look back at pharma news in the week to January 3, 2020
Being far behind the competition and not yet having secured US approval has not prevented the drug from attracting a $1.3 billion 2024 sales forecast, according to…
Le Figaro
The anticancer drug Merck wants to make the world's first drug
The anticancer Keytruda should soon climb to first place on the podium. Its turnover could cross the 20 billion dollar mark in 2023 and reach 22 billion the following…
FiercePharma
First generics to Bristol-Myers and Pfizer's Eliquis are here. But can they launch before 2026?
According to Evaluate Pharma’s 2020 Preview report published in December, Eliquis ranks as the No.4 biggest new sales generator, with a projected sales increase of $1.08…
FiercePharma
Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch
Allergan’s Ubrelvy, formerly known as ubrogepant, passed FDA gatekeepers Monday, becoming the first oral CGRP drug for the acute treatment of migraines….EvaluatePharma…
The Pharma Letter
PharmaMar inks deal worth up to $1 billion for lurbinectedin in the USA
Zepsyre carries 2024 sales forecasts of $163 million, implying an NPV of $600 million, according to EvaluatePharma.
